# SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia

> **NCT06435403** · — · RECRUITING · sponsor: **Michael Hoelscher** · enrollment: 1000 (estimated)

## Conditions studied

- SARS CoV 2 Infection
- COVID-19 Breakthrough
- COVID-19 Recurrent

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06435403
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435403, "SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06435403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*